Premium
Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease
Author(s) -
Jotkowitz Seymour
Publication year - 1983
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410140616
Subject(s) - physostigmine , placebo , crossover study , medicine , alzheimer's disease , clinical trial , disease , pathology , alternative medicine , acetylcholine
Ten patients with mild to severe Alzheimer's disease were treated for up to 10 months with 10 to 15 mg oral physostigmine daily or with placebo, according to a single blind, multiple crossover protocol. No clinically meaningful improvement occurred with physostigmine treatment.